New drug aims to shrink heart attack scar in major trial
Disease control
Not yet recruiting
This study tests whether an investigational drug called NL005 can reduce permanent heart muscle damage in people who have had a severe heart attack (STEMI) and undergone emergency artery-opening treatment. About 189 participants will receive either a low dose, high dose, or place…
Phase: PHASE2 • Sponsor: Beijing Northland Biotech. Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:10 UTC